Trial Profile

A multi-arm, multi-stage, randomized phase II/III trial of immunotherapy strategies in metastatic hormone-sensitive prostate cancer

Status: Active, no longer recruiting

Phase of Trial: Phase II/III

Latest Information Update: 14 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Docetaxel (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Hormone inhibitors
Indications Prostate cancer
Focus Therapeutic Use
Acronyms PROSTRATEGY

24 Oct 2023 Results assessing the feasibility and safety of androgen deprivation therapy plus docetaxel with or without nivolumab or ipilimumab-nivolumab in high-volume metastatic hormone-sensitive prostate cancer, presented at the 48th European Society for Medical Oncology Congress.
24 Oct 2023 Results reporting feasibility, safety and efficacy outcomes data from pilot phase with a median follow-up of 32.5 months presented at the 48th European Society for Medical Oncology Congress
25 Sep 2023 This trial has been completed, according to European Clinical Trials Database record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com